Dulaglutide, sold as Trulicity, is prescribed to a very large number of people for type 2 diabetes and has almost no alcohol-specific research attached to it. That combination is worth an article of its own, because “we do not know” is a real answer and it is not the same as “no”. This article is part of our GLP-1 and Alcohol hub.
If you are on Trulicity and you have noticed your drinking change, you are in a position where the internet will tell you either far too much or nothing at all.
# What the evidence looks like
Sparse, and honestly reported it comes to this.
No randomized trial has tested dulaglutide for alcohol. There is no equivalent of the semaglutide trial published in JAMA Psychiatry in 2025.
The most-cited item is a secondary analysis. Dulaglutide has been studied extensively for cardiovascular outcomes in diabetes, and a secondary analysis of that kind of trial has been pointed to as hinting at reduced alcohol use. A secondary analysis of a trial designed to answer a different question generates a hypothesis. It does not establish an effect, and it is not a finding you should weigh heavily.
Patient reports are comparatively few, though as with liraglutide this partly reflects prescribing patterns and attention rather than the drug. Dulaglutide is not part of the cultural conversation that semaglutide is, so fewer people are primed to notice and post about an alcohol change.
Animal work on dulaglutide specifically is limited, with most of the foundational rodent literature using other molecules.
# What absence of evidence means here
This distinction matters, so it is worth being precise.
Nobody has run the study that would detect an alcohol effect from dulaglutide. That is different from having run it and found nothing. The one case in this class where a trial was run and came back largely negative is exenatide, in JCI Insight in 2022, and even there a subgroup with obesity showed a reduction.
So the position on dulaglutide is genuine uncertainty. It activates the same GLP-1 receptors the mechanism argument depends on, which is a reason to think something might happen. It has not been tested, which is a reason not to expect anything in particular.
There is one specific caveat worth knowing. These drugs differ in how much they act centrally, in the brain, rather than only on the gut and pancreas. The alcohol hypothesis depends on central action. Whether dulaglutide reaches the relevant circuitry as effectively as semaglutide does is not something you can assume from them sharing a receptor target, and it is one of the reasons the class-effect assumption deserves the scepticism set out in which GLP-1 medications have evidence for alcohol cravings.
# Practical points if Trulicity is your drug
Drinking on it carries the same considerations as the rest of the class. Nausea is the common side effect and alcohol aggravates it, absorption timing changes because gastric emptying slows, and the serious interaction is with insulin or a sulfonylurea, where alcohol raises the risk of hypoglycaemia. All of that is covered in can you drink alcohol on a GLP-1.
Switching drugs to chase an alcohol effect is not supported. It would mean leaving a drug that is working for your diabetes in pursuit of an effect that is unproven in the drug you would move to and only modestly evidenced in any of them.
If your drinking has changed, that is worth reporting. Given how little exists on this drug, an observation from a Trulicity patient is more informative than the same observation from a semaglutide patient, simply because so few have been recorded.
# Central action, and why it is the crux
The mechanism behind this whole topic requires a drug to influence receptors in the brain, not only in the gut and pancreas. This is where dulaglutide’s uncertainty is concentrated.
These molecules are large, and how readily each one reaches central targets differs. Some effects appear to be mediated indirectly, through signalling from the gut and the vagus nerve, rather than by the drug crossing into the brain in quantity. The balance between direct and indirect action is not identical across the class.
That matters because a drug could be excellent at lowering blood sugar, which is largely a peripheral job, while doing comparatively little to reward circuitry. Nobody has established where dulaglutide sits on that spectrum for alcohol-relevant regions.
So the uncertainty here is not merely that the trial has not been run. There is a specific, plausible reason the answer might turn out to be no, alongside a specific, plausible reason it might turn out to be yes. That is a genuinely open question rather than an assumed yes awaiting confirmation.
# What to do if you notice a change
Write it down as it happens. Not reconstructed later. The value is in the dates lining up with your dose history.
Give it more than a fortnight. Drinking varies week to week for reasons that have nothing to do with medication, and a short window will mislead you in either direction.
Separate desire from aversion. If alcohol has become unappealing, that is one thing. If it makes you feel unwell, that is a side effect reducing your intake, which is a different finding and a less durable one.
Take it to your prescriber rather than to a forum. For a drug this under-discussed, forum answers will mostly be extrapolated from semaglutide, and the whole point of this page is that the extrapolation is not safe.
# Why this page exists at all
It would be easy to leave dulaglutide out of a hub like this, on the grounds that there is nothing to report. That would be a mistake for two reasons.
The first is that a lot of people take it. Someone on Trulicity who notices their drinking drop deserves an answer, and “this drug is not part of the conversation” is a more useful answer than silence or than the assumption that everything written about Ozempic applies to them.
The second is that the honest state of knowledge is itself the information. Most coverage of GLP-1 drugs and alcohol treats the class as interchangeable, which quietly implies that the research applies to whichever one you happen to be on. It does not. Knowing that your drug is the least-studied one changes how much weight to put on what you read elsewhere, and it should.
# Dulaglutide against the rest of the class
For anyone weighing where their drug sits, the ranking on alcohol evidence runs roughly like this.
Semaglutide has the most: large record-based analyses and a small randomized trial. Exenatide has the most rigorous single trial, which was largely negative outside a subgroup. Tirzepatide has volume of patient reports without a trial. Liraglutide has supporting brain-imaging work but almost nothing on drinking. Dulaglutide has least of all.
That ordering is about how much anyone has looked, not about how strong each drug is. Prescribing volume, media attention and commercial interest drive research agendas, and dulaglutide has been a quiet, dependable diabetes drug rather than a cultural phenomenon. Being under-researched and being ineffective produce the same empty search results.
The comparison across all of them is in which GLP-1 medications have evidence for alcohol cravings.
# How AlcoLog helps
When published evidence is thin, your own record is a larger share of what you actually have to go on.
AlcoLog logs each drink in one tap and tracks medication doses, including GLP-1 agonists, so your dose timeline and your drinking sit together. For a weekly injection like Trulicity, the useful comparison is the weeks before and after a dose change, and that is a comparison memory handles poorly over months.
Weekly and monthly views turn a gradual shift into a visible trend. If you want to raise this with a prescriber who has probably not been asked about dulaglutide and alcohol before, arriving with a chart rather than an impression makes the conversation a different one.
Medication is deliberately excluded from the AlcoScore. Your dose log informs you, it is not graded. Data stays on your device, no account or email is required, and export gives you something concrete to share.
